Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2012
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XC13
|
| gptkbp:combines |
gptkb:trastuzumab
docetaxel |
| gptkbp:contraindication |
pregnancy
|
| gptkbp:developedBy |
gptkb:Genentech
|
| gptkbp:drugClass |
gptkb:monoclonal_antibody
|
| gptkbp:genericName |
gptkb:pertuzumab
|
| https://www.w3.org/2000/01/rdf-schema#label |
Perjeta
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:HER2/neu_receptor
|
| gptkbp:marketedAs |
gptkb:Roche
|
| gptkbp:mechanismOfAction |
HER2 receptor antagonist
|
| gptkbp:pregnancyCategory |
D
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue hair loss peripheral neuropathy rash |
| gptkbp:usedFor |
gptkb:cancer
gptkb:HER2-positive_breast_cancer |
| gptkbp:bfsParent |
gptkb:Genentech
|
| gptkbp:bfsLayer |
5
|